Business Wire

CA-STARCITY

23.12.2020 17:02:14 CET | Business Wire | Press release

Share
Starcity Is Launching Invest.starcity.com in Partnership With Republic Real Estate to Allow Accredited Investors to Back Coliving Real Estate Development Projects

Starcity, one of the fastest-growing technology enabled real estate owners and operators, announced today the launch of invest.starcity.com . This first of its kind investment platform allows accredited investors the opportunity to back Starcity development projects.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201223005265/en/

"We are thrilled to launch invest.starcity.com , so investors of all kinds have the opportunity to back Starcity developments. Typically, large-scale institutional investments are reserved for closed-door dealings, and we're excited to open these deals up to democratize access for more people," said Jon Dishotsky, CEO and co-founder of Starcity.

The first project will be Starcity Minna, a fully approved, 16-story, 270 unit, highrise in the South of Market (SoMa) district of San Francisco. Starcity will operate the 122,845 gross square feet development as a furnished residential community targeting middle and low-income residents of San Francisco with a convenient, value-oriented, and highly amenitized residential lifestyle offering.

"Despite the fall in rents in San Francisco this past year, the city remains largely out of reach for working-class professionals. Very few individuals can afford a $3,000 to $4,000 apartment, and we're excited to deliver units that start in the $900-$1,000 range. This level of affordability has rarely been achieved in San Francisco. Furthermore, major investors and occupiers like Amazon, Blackstone, Google, KKR, Starwood, and others have announced investment initiatives into San Francisco during the pandemic, and Brookfield is going vertical on projects right next door to Minna, so the time is right. And despite noise in the headlines, San Francisco has been a consistently above-market return investment geography due to the supply constraints and demand drivers," said Mo Sakrani, Chief Investment Officer and co-founder of Starcity.

Starcity Minna will comprise 15 residential levels over a welcoming ground floor lobby and event space attached to an outdoor patio, as well as a bike repair and storage facility. Each residential level (FL 2-16) hosts 18 private units with ensuite bathrooms and features a 1,000 square feet amenity space that includes a chef's-style kitchen and dining area, lounge, and media area with expansive city views. The building is topped by a large landscaped rooftop terrace, offering panoramic views of San Francisco.

Starcity Minna will consist of steel modules over a concrete ground-floor podium, tied-together with a concrete elevator core. Four primary module types will make up the private units, corridors, common areas, and stairs. Each module will arrive fully outfitted with furnishings, bathroom and kitchen fixtures, piping, and wiring.

Modular construction is well suited for Starcity Minna for two main reasons. First, San Francisco is one of the most expensive cities to build in globally, and modular construction shifts those costs to an off-site factory. Second, the standardized unit layout is conducive to manufacturing.

"San Francisco remains one of the strongest apartment rental markets in the country. We are delighted to provide access for individual investors into a well-located project poised to capitalize on the city’s next wave of growth and appreciation through technology powered by the Republic platform. Real estate is an $8.9 trillion market, and it's time for everybody to own a piece of it,” said Janine Yorio, Head of Real Estate at Republic.

With this new offering Starcity is reimagining the entire spectrum of real estate:

  • On the investment side by allowing people access to build wealth.
  • On the housing side by making living in cities accessible.
  • On the construction side, by exploring modular to bring the cost of construction down.

This template should create a path for major affordable housing in any city that has income inequality that has been further exacerbated by the pandemic. Real estate has long been a stodgy investment industry, designed to keep the main street investor out — Starcity aims to change that with this launch.

Starcity is one of the leading coliving companies and operates over 1,500 units globally, with over 3,000 units in its development and operations pipeline throughout North America and Western Europe and over 10,000 units in negotiations. Starcity is backed by Y Combinator, NEA, Social Capital, Tribe Capital, Bullpen Capital, Deciens, and Industry Ventures.

Starcity is conducting a Rule 506(c) offering solely to accredited investors. Republic Real Estate has provided the technology to enable Invest.starcity.com.

Social Media:

https://facebook.com/starcity

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye